Valuation : Sensorion

Market Cap 129M 150M 121M 110M 206M 14.19B 207M 1.43B 555M 7.25B 562M 550M 23.08B P/E 2026 *
-33.3x
P/E 2027 * -5.56x
Enterprise Value -3.32M -3.86M -3.12M -2.85M -5.32M -366M -5.35M -37.01M -14.32M -187M -14.5M -14.18M -595M EV / Sales 2026 *
-0.15x
EV / Sales 2027 * 20.1x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
1 day+1.40%
1 week-4.70%
Current month-5.76%
1 month-13.33%
3 months-32.22%
6 months-39.35%
Current year-24.78%
1 week 0.24
Extreme 0.238
0.27
1 month 0.24
Extreme 0.238
0.3
Current year 0.22
Extreme 0.222
0.81
1 year 0.22
Extreme 0.222
0.81
3 years 0.15
Extreme 0.1544
1.04
5 years 0.15
Extreme 0.1544
2.29
10 years 0.15
Extreme 0.1544
7.74
Manager TitleAgeSince
Chief Executive Officer 59 01/06/2026
Director of Finance/CFO - 26/06/2024
Chief Tech/Sci/R&D Officer - 11/12/2023
Director TitleAgeSince
Director/Board Member - 09/03/2015
Director/Board Member 43 -
Chairman 61 30/03/2023
Date Insider Type Main position Quantity % Market Cap. Importance
06/02/26
Redmile Biopharma Investments III LP
BuyCompany 18,928,571 6.2956%
31/01/26
Sofinnova Partners SAS
BuyCompany 10,714,285 3.5636%
18/04/24
Redmile Biopharma Investments III LP
BuyCompany 2,781,914 1.0091%
Change 5-day change 1-year change 3-year change Capi.($)
+1.40%-4.70%-16.06%-64.79% 150M
-0.82%-3.77%-2.49%+14.92% 48.41B
+0.13%+0.13%+411.77%+554.21% 45.01B
-1.82%+1.89%+40.25%+23.28% 44.07B
-2.59%-2.76%+0.66%+81.05% 40.73B
-1.72%-3.07%+13.76%+43.40% 33.21B
-0.76%+3.28% - - 17.77B
-0.00%+1.25%+20.00%+117.81% 16.5B
-0.56%-0.50%+11.39%+31.41% 14.45B
-1.86%+0.38%+74.94%+41.88% 13.77B
Average -0.80%-0.53%+61.58%+93.69% 27.41B
Weighted average by Cap. -1.07%-0.13%+86.60%+134.22%

Financials

2026 *2027 *
Net sales 21.86M 25.42M 20.56M 18.77M 35.02M 2.41B 35.2M 244M 94.27M 1.23B 95.46M 93.38M 3.92B 6.4M 7.44M 6.02M 5.49M 10.25M 705M 10.3M 71.28M 27.58M 360M 27.93M 27.32M 1.15B
Net income -237K -275K -223K -203K -379K -26.1M -381K -2.64M -1.02M -13.34M -1.03M -1.01M -42.45M -36.12M -42.01M -33.98M -31.01M -57.87M -3.98B -58.17M -403M -156M -2.04B -158M -154M -6.48B
Net Debt -132M -154M -124M -113M -211M -14.55B -213M -1.47B -569M -7.44B -576M -564M -23.67B -
Logo Sensorion
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
63
Date Price Change Volume
08/09/26 0.2535 +1.40% 470,693
07/09/26 €0.2500 +0.60% 565,108
04/09/26 €0.2485 -2.93% 1,206,346
03/09/26 €0.2560 -0.39% 1,181,678
02/09/26 €0.2570 -3.38% 644,753
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.2500EUR
Average target price
1.138EUR
Spread / Average Target
+355.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALSEN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!